- $2,000/year IRA out-of-pocket Medicare drug cap (2025) — down from $10,000+ for some seniors
- $35/month insulin cap for Medicare recipients — 3.3M beneficiaries affected
- 87% of Medicare beneficiaries support the $2,000 cap (KFF, 2026)
- 10 drugs with negotiated prices taking effect 2026 — reductions of 38-79% off list price
What the IRA Changed — and What's Threatened
Before the IRA, Medicare Part D had no cap on out-of-pocket drug costs. Seniors with serious chronic conditions — diabetes requiring insulin, blood clotting disorders, certain heart conditions — could face annual drug bills of $10,000 or more. The IRA's $2,000 cap, which took effect in 2025, represents one of the most concrete and immediate improvements in healthcare affordability for seniors in decades. 3.3 million Medicare insulin users immediately benefited from the $35 monthly cap when it took effect in 2023.
Republican budget reconciliation legislation under consideration in 2026 targets multiple IRA healthcare provisions to generate budget savings. The specific provisions at risk include: the expansion of negotiated drugs beyond 10 (Republicans propose to limit the program's reach), the out-of-pocket cap structure (proposals to raise the $2,000 threshold), and continuation of insulin pricing. The pharmaceutical industry has lobbied heavily for these rollbacks, contributing to Republican campaign committees at record levels.
The political risk is acute. Voters over 65 turn out in midterm elections at rates 20-30 points higher than voters under 30. Any legislation that visibly raises drug costs for Medicare beneficiaries — or that can be credibly characterized as doing so in campaign advertising — poses an existential threat to Republican incumbents in competitive districts. Several Republican members have already publicly stated they will not support changes to the insulin cap or the $2,000 out-of-pocket limit.